NCT05361668 2026-03-19
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Phase 2 Completed
Crinetics Pharmaceuticals Inc.
Barbara Ann Karmanos Cancer Institute
TerSera Therapeutics LLC
University of Kentucky
Ipsen
Ipsen
Camurus AB
Novartis
University of Aarhus